Mass Spectrometry is key technology for studying critical molecules and pathways. Defining molecular targets is crucial for the process of drug development.
In our group, we are focused on using proteomics, mass spectrometry and biochemical approaches to understand disease processes.
Proteomics and Mass Spectrometry
The group has expertise in proteomics based methodologies and hosts a platform containing a variety of chromatography equipment and mass spectrometers.
Kessler Group Sky Garden London Nov 2018
Our team
-
Benedikt Kessler
Professor of Biochemistry and Mass Spectrometry
-
Philip Charles
Bioinformatician/Statistician
-
Andreas Damianou
Postdoctoral Researcher
-
Roman Fischer
Associate Professor and Head of Discovery Proteomics Facility
-
Raphael Heilig
Research Assistant - Mass Spectrometry
-
Svenja Hester
Research Assistant (Maternity cover)
-
Hannah Jones
Postdoctoral Researcher
-
Darragh O'Brien
Postdoctoral Researcher
-
Hannah Scott
Research Assistant
-
Paolo Spingardi
DPhil Student
-
Bohan Yu
Visiting Student
Selected publications
-
The deubiquitinase TRABID stabilises the K29/K48-specific E3 ubiquitin ligase HECTD1
Journal article
Harris LD. et al, (2020), Journal of Biological Chemistry, jbc.RA120.015162 - jbc.RA120.015162
-
Detection and Quantification of Novel C‐terminal TDP‐43 Fragments in ALS‐TDP
Journal article
Feneberg E. et al, (2020), Brain Pathology
-
CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis
Journal article
Thompson AG. et al, (2020), Clinical Proteomics, 17
-
Subclinical effects of remote ischaemic conditioning in human kidney transplants revealed by quantitative proteomics
Journal article
Thorne AM. et al, (2020), Clinical Proteomics, 17
-
Cytoskeletal disorganization underlies PABPN1-mediated myogenic disability
Journal article
Olie CS. et al, (2020), Scientific Reports, 10